Cleveland Clinic - Taussig Cancer Center
Taussig Cancer Institute
Cleveland, OH
Not yet accepting
ELRiSE MDS
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions (ELRiSE MDS)
- Activin Receptor IIA Inhibitor
- Randomization
- Phase 3
Accepting patients
RALLY-MF
RALLY-MF: A Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and AnemiaA Phase 1b/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis and Anemia
- Monoclonal Antibody
- Hemojuvelin (HJV)
- Randomization
- Monotherapy
- Phase 1/2
- Has results
Accepting patients
IRAK
Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
- IRAK 1 Inhibitor
- IRAK 4 Inhibitor
- Phase 1/2
- Has results
Accepting patients
RENEW
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Activin Receptor IIA Inhibitor
- Closed Label (Masked)
- Placebo
- Phase 3
Not currently accepting
Luspatercept and Lenalidomide (L2)
A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
- Erythroid Maturation Agent (EMA)
- Immunomodulatory Drug
- Red Blood Cell Stimulant
- Phase 1/2
- Monoclonal Antibody
- CD70
- Phase 1
Accepting patients
Safety Study of Cord Blood Units
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation
- Allogeneic Stem Cell Transplant
- Phase 2
Not currently accepting
Eltrombopag
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
- Thrombopoietin Receptor Agonist (TPO-RA)
- White Blood Cell Stimulant
- Phase 2
Not yet accepting
Olutasidenib Maintenance
Pilot Trial of Olutasidenib Maintenance Post Allogeneic Hematopoietic Cell Transplantation in Patients Carrying IDH1 Mutation With AML, MDS, or CMML Disease
- IDH1 Inhibitor
- Phase 1
Accepting patients
Eganelisib
A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib as Monotherapy and in Combination With Cytarabine in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- PI3K Inhibitor
- Randomization
- Phase 1